DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
DBVT Stock Chart & Stats
$20.45
$0.34(9.80%)
At close: 4:00 PM EST
$20.45
$0.34(9.80%)
Day’s Range― - ―
52-Week Range$6.69 - $26.19
Previous CloseN/A
Volume52.91K
Average Volume (3M)267.23K
Market Cap
$1.18B
Enterprise Value$545.53M
Total Cash (Recent Filing)$194.17M
Total Debt (Recent Filing)$21.68M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
May 04, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding55,670,418
10 Day Avg. Volume264,167
30 Day Avg. Volume267,229
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)3.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.42
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.89
Enterprise Value/Ebitda-4.06
Forecast
1Y Price Target
$46.40Price Target Upside126.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$5.34M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyPhase 3 results showing that Viaskin Peanut met regulatory success criteria while demonstrating consistent safety and low discontinuation rates support a credible approval pathway for pediatric patients.
Commercial Readiness And FundingA strengthened cash position and recent financing provide resources to build pre-commercial inventory and recruit commercial and regulatory leadership ahead of a potential launch.
Regulatory CatalystsUpcoming regulatory filings and a pediatric safety study for the Viaskin Peanut program could unlock approval milestones that materially affect commercial prospects.
Bears Say
Financing Risk And DilutionHigh cash burn and a limited cash runway increase the likelihood of additional capital raises before commercialization, creating potential dilution risk for existing shareholders.
Modeling And Tax Recognition RiskAn identified error related to carrying forward corporate tax losses in France highlights forecasting or reporting vulnerabilities that could undermine investor confidence.
Valuation RevisionAnalyst updates to the valuation model that produced a lower price target signal reduced market expectations and may weigh on the stock.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $6.69 and its highest was $26.18 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
DBV Technologies SA - American’s market cap is $1.18B.
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is May 04, 2026 which is in 25 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Mar 26, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.062.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -0.15.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 55,670,418 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -1.039%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Currently, no hedge funds are holding shares in DBVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DBV Technologies SA - American Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.40 (126.89% Upside)
$46.40 (126.89% Upside)
Blogger Sentiment
Bearish
DBVT Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $2.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
213.23%
12-Months-Change
Fundamentals
Return on Equity
-189.50%
Trailing 12-Months
Asset Growth
255.96%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBVT Stock 12 Month Forecast
Average Price Target
$46.40
▲(126.89% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
PureTech Health
―
Lexeo Therapeutics, Inc.
―